- Previous Close
3.9900 - Open
3.8500 - Bid 3.6800 x 300
- Ask 3.7500 x 200
- Day's Range
3.7100 - 3.9000 - 52 Week Range
3.7100 - 7.6300 - Volume
946,124 - Avg. Volume
869,054 - Market Cap (intraday)
476.521M - Beta (5Y Monthly) 1.41
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0500 - Earnings Date May 6, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.90
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. The company offers aurora and northern lights systems delivers cell analysis; aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; enhanced small particle detection; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. It serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. The company distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
cytekbio.comRecent News: CTKB
View MorePerformance Overview: CTKB
Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CTKB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CTKB
View MoreValuation Measures
Market Cap
476.52M
Enterprise Value
215.68M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.42
Price/Book (mrq)
1.20
Enterprise Value/Revenue
1.08
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-3.00%
Return on Assets (ttm)
-2.91%
Return on Equity (ttm)
-1.53%
Revenue (ttm)
200.45M
Net Income Avi to Common (ttm)
-6.02M
Diluted EPS (ttm)
-0.0500
Balance Sheet and Cash Flow
Total Cash (mrq)
277.86M
Total Debt/Equity (mrq)
4.30%
Levered Free Cash Flow (ttm)
36.25M